Search Results

for <5% of all cases. 2 IMTs most often present with signs and symptoms restricted to the areas affected; however, 15% to 30% of people present with fever, weight loss, malaise, microcytic anemia, elevated erythrocyte sedimentation rate

delay in obtaining remaining tissue from the patient's FNA, the specimen tested positive for NMC with strong, diffuse NUT staining ( Figure 2 ). In the interim, the patient experienced worsening bone pain, dyspnea, and fever, and was hospitalized

pain (43%), fevers (13%), weight loss (10%), and splenic pain (4%). MPN-associated symptom burden and inability to perform activities of daily living (ADLs) were associated with worsening cytopenias and splenomegaly. 5 However, distress, anxiety, and

reduction. The treatment course with trametinib and dabrafenib continued for a total of 9 months. The patient experienced mild pyrexia (grade I fever according to CTCAE version 5.0.), which required treatment interruption for 4 days before later resuming the

transplantation: analysis of factors associated with infection . Oral Surg Oral Med Oral Pathol 1990 ; 70 : 286 – 293 . 60. Bergmann OJ Mogensen SC Ellermann-Eriksen S Ellegaard J . Acyclovir prophylaxis and fever during remission-induction therapy

who’ve been through the process already. The patient and family experience has been improved due to Moffitt’s nursing team’s efforts to provide dedicated education on the common side effects for CAR T-cell therapy, such as high fevers, neurotoxicity

65 years. Tumor flare reactions occurred in 71% of patients, but were grade 1 or 2 in nearly all cases. The most common grade 3 or 4 toxicity was neutropenia, which was reported in 49% of patients. Neutropenic fever occurred in 4 patients (6%). 24

severe chronic neutropenia) based on a randomized controlled trial involving 123 patients. 109 In this study, daily treatment with subcutaneously administered G-CSF normalized neutrophils in most patients and prevented fever, mouth ulcers, and infections

, although they were not severe and were reversible. These reactions included mild myalgias, facial flushing, low-grade fever, headache, bone discomfort, nausea, and dyspnea. 106 A side-effect profile of GM-CSF, completed several years later, reported a

less than 20,000/μL for fever, sepsis, uncontrolled infections, a blood urea nitrogen of greater than 70, or veno-occlusive disease. One institution with a usual threshold of less than 10,000/μL increases this threshold to less than 20,000/μL for